BE-CAR33碱基编辑通用型CAR33 T细胞治疗急性髓系白血病的1期可行性试验
该1期开放标签非随机单中心研究评估了通用供者来源碱基编辑抗CD33 CAR T细胞(BE-CAR33)在异基因造血干细胞移植前治疗复发/难治性急性髓系白血病的安全性和可行性。3例入组患者及1例同情用药成人接受氟达拉滨、环磷酰胺和阿仑单抗预处理后输注1.2-1.8×10^6/kg BE-CAR33细胞,出现≤2级细胞因子释放综合征、3级神经毒性、4级血细胞减少和短暂皮疹,2例微小残留病降低并桥接至移植。虽未达到主要终点,但首次人体试验证明了通用型碱基编辑CAR T细胞方法的可行性。
要点
- BE-CAR33为通用供者来源、多重碱基编辑敲除TRAC、CD52和CD7的抗CD33 CAR T细胞。
- 预处理后输注1.2-1.8×10^6/kg,出现≤2级CRS、3级神经毒性和4级血细胞减少。
- 2例患者微小残留病降低并成功桥接至异基因造血干细胞移植。
核心结论
- 首次人体试验证明通用型碱基编辑CAR T细胞方法治疗AML具有可行性,虽未达到主要终点。
研究设计与样本
- 开放标签、非随机、单中心1期研究(ISRCTN14430213),评估BE-CAR33在异基因造血干细胞移植前治疗AML的安全性、可行性和活性。
- 筛选5例、入组3例年龄小于16岁的复发/难治性AML患者,另1例成人经同情用药接受BE-CAR33。
主要发现
- 治疗中出现的不良事件包括细胞因子释放综合征(≤2级)、神经毒性(3级)、血细胞减少(4级)和短暂皮疹。
- 2例患者微小残留病降低并接受异基因造血干细胞移植。
- 系列流式细胞术、嵌合率定量和载体拷贝数分析追踪BE-CAR33 T细胞至移植期间被清除。
- 差异表达基因包括编辑特征,并从生产相关谱转向扩增后效应和耗竭谱。
关键数值与推荐
- 预处理方案为氟达拉滨、环磷酰胺和阿仑单抗,随后输注1.2至1.8×10^6个BE-CAR33细胞/千克。
临床怎么用
- BE-CAR33可作为复发/难治性AML患者桥接异基因造血干细胞移植的潜在通用型细胞治疗选择。
局限性
- 主要终点未达到。
- 样本量小(入组3例加同情用药1例),为非随机单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cell therapy for acute myeloid leukemia (AML) is constrained by antigen heterogeneity and shared expression with healthy compartments, and there are often challenges in obtaining autologous T cells from heavily pretreated patients. To address these challenges, we developed universal donor-derived, base-edited, anti-CD33 CAR T cells (BE-CAR33) that used precise multiplexed cytidine deamination to simultaneously disrupt the TRAC, CD52, and CD7 loci to prevent graft-versus-host disease and evade immunotherapy effects. An open-label, nonrandomized, single-center phase 1 study (ISRCTN14430213) evaluated the safety, feasibility, and activity of BE-CAR33 cell therapy ahead of allogeneic stem cell transplantation (allo-SCT) for patients with AML. Eligible participants were aged less than 16 years with relapsed/refractory AML. Five patients were screened, and three were enrolled; one additional adult received BE-CAR33 through compassionate access. Participants received fludarabine, cyclophosphamide, and alemtuzumab followed by 1.2 to 1.8 × 106 BE-CAR33 cells per kilogram. Treatment-emergent adverse events included cytokine release syndrome (grade ≤2), neurotoxicity (grade 3), cytopenias (grade 4), and transient rashes. Two patients demonstrated reduced minimal residual disease and proceeded to allo-SCT. Serial flow cytometry, chimerism quantification, and vector copy number analyses tracked BE-CAR33 T cells until elimination during transplant. Differentially expressed genes included editing signatures and switched from manufacturing-related toward postexpansion effector and exhaustion profiles. Although primary end points were not met, this first-in-human study demonstrated the feasibility of an "off-the-shelf" base-edited CAR T cell approach and informs future multiantigen strategies against AML.
引用
- Georgiadis C, Chiesa R, Rashed H, et al. A phase 1 feasibility trial of BE-CAR33, an "off-the-shelf" base-edited CAR33 T cell therapy for acute myeloid leukemia. Sci Transl Med. 2026. PMID: 42616838. doi:10.1126/scitranslmed.aei0875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。